Equities

Curaleaf Holdings Inc

CURA:TOR

Curaleaf Holdings Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)7.62
  • Today's Change-0.10 / -1.30%
  • Shares traded570.15k
  • 1 Year change+105.95%
  • Beta1.4842
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Curaleaf Holdings, Inc. is an international provider of consumer cannabis products. The Company and its brands, including Curaleaf, Select, Grassroots, JAMS, Find and Zero Proof provide selection and accessibility across the medical and adult use markets. It operates in approximately 17 states and owns and operates 147 dispensaries and 21 cultivation sites with a focus on states, including Arizona, Florida, Illinois, Massachusetts, New Jersey, New York and Pennsylvania. It cultivates, processes, markets and/or dispenses a range of permitted cannabis products across its operating markets, including flower and pre-rolls, dry-herb vaporizer cartridges, concentrates for vaporizing such as pre-filled vaporizer cartridges and disposable vaporizer pens, concentrates for dabbing, such as mints, topical balms and lotions, tinctures, lozenges, capsules and edibles. Through Curaleaf International Holdings Limited, it has a supply and distribution network throughout the European market.

  • Revenue in CAD (TTM)1.84bn
  • Net income in CAD-322.40m
  • Incorporated2014
  • Employees5.65k
  • Location
    Curaleaf Holdings Inc420 Lexington AvenueNEW YORK 10170United StatesUSA
  • Phone+1 (781) 451-0117
  • Websitehttps://ir.curaleaf.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
CURA:TOR since
announced
Transaction
value
Northern Green Canada IncAnnounced19 Mar 202419 Mar 2024Announced9.17%--
Cronos Group IncRumoured06 Jul 202306 Jul 2023Rumoured70.09%--
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Arrowhead Pharmaceuticals Inc48.28m-640.79m4.19bn525.00--6.36--86.73-4.24-4.240.31893.900.0384----67,567.62-51.72-20.02-57.39-24.65-----1,346.13-61.79---80.000.00---1.0371.68-16.59--162.38--
Guardant Health Inc821.73m-627.33m4.22bn1.78k--45.23--5.14-3.92-3.925.170.56070.37544.377.03339,362.00-28.66-22.26-33.02-24.5960.3764.62-76.34-97.075.66-59.550.9435--25.4544.1426.76--0.2786--
Summit Therapeutics Inc0.00-157.92m4.24bn105.00--70.50-----0.1657-0.16570.000.0630.00----0.00-53.76-77.32-59.38-86.35-------20,989.46---118.810.6934---100.00---680.54---4.84--
Hims & Hers Health Inc1.31bn-3.20m4.26bn1.05k--9.07388.853.26-0.016-0.0164.461.612.336.68--917,209.40-0.5704---0.6968--82.41---0.245--2.48------65.49--64.15------
Biohaven Ltd0.00-703.93m4.49bn239.00--10.14-----6.83-6.830.003.680.00----0.00-99.74---123.66--------------0.00------28.43------
SpringWorks Therapeutics Inc36.01m-461.51m4.52bn305.00--5.85--125.58-5.15-5.150.40077.660.0432----86,731.15-55.31-36.97-60.58-39.4993.86---1,281.78-2,176.466.77--0.00-------17.19--90.68--
Ultragenyx Pharmaceutical Inc602.40m-834.83m4.74bn1.28k--24.80--7.86-8.02-8.025.751.690.3291.616.18346,854.20-45.59-33.35-55.09-38.3088.5993.13-138.58-154.712.28--0.00--19.5253.1814.25--62.91--
Alvotech SA127.10m-750.96m4.90bn999.00------38.57-2.40-2.400.4109-3.490.1052.201.3993,475.48-62.04---81.72---72.26---590.83--0.4614-1.297.52--9.84---7.43------
Curaleaf Holdings Inc1.84bn-322.40m4.93bn5.65k--4.06--2.68-0.4418-0.51332.521.880.41983.0724.81325,875.10-7.65-7.38-9.75-8.6745.4543.30-18.23-18.120.35790.35360.4585--5.5877.2111.09--8.92--
Axsome Therapeutics Inc341.67m-403.40m4.95bn545.00--25.22--14.48-6.38-6.385.413.030.5372.113.43460,592.70-63.40-64.55-85.88-82.2390.12---118.07-227.053.09-55.540.556--440.80---27.84--77.86--
Insmed Inc429.42m-1.02bn5.01bn912.00------11.67-5.23-5.232.20-3.130.23570.89719.32345,936.40-55.80-40.96-72.23-46.8878.0777.99-236.74-212.921.61-16.081.64--24.3998.78-55.66---2.15--
Simply Good Foods Co1.72bn191.58m5.11bn271.0026.952.2823.182.961.391.3912.5316.480.59776.918.564,671,908.006.653.666.953.8337.2638.9011.126.803.099.260.12610.006.3323.5623.0313.6547.09--
Crinetics Pharmaceuticals Inc2.69m-320.49m5.52bn290.00--4.61--2,053.38-3.77-3.770.031511.140.0031--0.36536,806.90-35.57-42.53-37.86-45.36-----11,641.13-5,446.39----0.00---15.2810.57-30.88--34.65--
Alkermes Plc2.35bn816.59m5.56bn2.10k6.903.266.152.373.502.5310.057.420.85321.325.81821,991.4029.651.3438.771.7485.3183.3234.762.122.77--0.18780.0049.618.741,665.99---7.10--
Data as of May 17 2024. Currency figures normalised to Curaleaf Holdings Inc's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.